Abstract
Although much experience had been gained with the agents available for ADEPT studies in xenografted mice (Bagshawe et al., 1988), their translation into the clinic was in many ways a step into the unknown. It seemed possible, even likely, that new and unforeseen problems would emerge. To introduce a series of agents that would interact with each other in vivo was in itself a cause for some apprehension. One of the main objectives of the first study was to identify new problems, to obtain guidance on the dose levels of the various components likely to be effective, to test the potential of an immunosuppressive agent to allow more than one cycle of therapy to be given, and if possible, to demonstrate efficacy (Bagshawe et al., 1995)
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Bagshawe, K. D., Sharma, S. K., Springer, C. J., and Antoniw, P., 1995, Antibody directed enzyme prodrug therapy: a pilot-scale clinical trial, Tumor Targeting 1:17–29.
Bagshawe, K., Springer, C. J., Searle, F., Antoniw, R, Sharma, S. K., Melton, R. G., and Sherwood, R. F., 1988, A cytotoxic agent can be generated selectively at cancer sites, Br. J. Cancer 58:700–703.
Blakey, D. C., Burke, R J., Davies, D. H., Dowell, R. I., East, S. J., Eckersley, K. R, Fitton, J. E., Mcdaid, J., Melton, R. G., Niculescu-duvaz, I. A., Pinder, P. E., Sharma, S. K., Wright, A. E, and Springer, C. J., 1996, ZD2767, an improved system for antibody-directed enzyme prodrug therapy that results in tumor regressions in colorectal tumor xenografts, Cancer Res. 56:3287–3892.
Blakey, D. C., Valcaccia, B. E., East, S., Wright, A. F., Boyle, E. H., Springer, C. J., Burke, R. B., Melton, R. G., and Bagshawe, K. D., 1993, Antitumour effects of an antibody-carboxypeptidase G2 conjugate in combination with a benzoic acid mustard prodrug, Cell Biophys. 22:1–8.
Deierhoi, M. H., Kauffman, R. S., Hudson, S. L., Barber, W. H., Curtis, J. J., Julian, B. A., Gaston, R. S., Laskow, D. A., and Diethelm, A. G. (1993) Experience with mycophenolate mofetil (RS61443) in renal transplantation at a single center, Ann. Surg. 217:476–482.
Dhingra, K., Fritsche, H., Murray, J. L., Lobuglio, A. E, Khazaeli, M B., Kelley, S, Tepper, M. A., Grasala, D., Buzdar, A., and Valero, V., 1995, Phase I clinical and pharmacological study of suppression of human antimouse antibody response to monoclonal antibody L6 by deoxyspergualin, Cancer Res. 55:3060–3067.
Green, A. J., Dewhurst, S. E., Begent, R. H. J., and Riggs, S. J., 1990, Accurate quantitation of 1311 distribution by gamma camera imaging, Eur. J. Nucl. Med. 16:361–365.
Martin, J., Stribbling, S. M., Poon, G. K., Begent, R. H. J., Napier, M., Sharma, S. K., and Springer, C. J., 1997, Antibody-directed enzyme prodrug therapy: Pharmacokinetics and plasma levels of prodrug and drug in phase I clinical trial, Cancer Chemother. Pharmacol. 40:189–201.
McCulloch, J. L., Chabner, B. A., and Bertino, J. R., 1971, Purification and properties of carboxypeptidase Gl, J. Biol. Chem. 246:7207–7213.
Melton, R. G., Boyle, J. M. B., Rogers, G. T., Burke, P., Bagshawe, K. D., and Sherwood, R. E, 1993, Optimisation of small-scale coupling of A5B7-monoclonal antibody to carboxypeptidase G2, J. Immunol. Methods 158:49–56.
Sharma, S. K., Bagshawe, K. D., Burke, P. J., Boden, J. A., Rogers, G. T., Springer, C. J., Melton, R. G., and Sherwood, R. F., 1994, Galactosylated antibodies and antibody-enzyme conjugates in antibody-directed enzyme prodrug therapy, Cancer 73:1114–1120.
Springer, C. J., Antoniw, R, Bagshawe, K. D., Searle, F., Bisset, G. M. E, and Jarman, M., 1990, Novel prodrugs which are activated to cytotoxic alkylating agents by carboxypeptidase G2, J. Med. Chem. 33:677–681.
Springer, C. J., Antoniw, P., Bagshawe, K. D., and Wilman, D. E. V., 1991, Comparison of half-lives and cytotoxicity of N-mesyloxyethylbenzoyl compounds, products of prodrugs in antibody-directed enzyme prodrug therapy (ADEPT), Anticancer Drug Des. 6:467–479.
Stribbling, S. M., Martin, J., Pedley, R. B., Boden, J. A., Sharma, S. K., and Springer, C. J., 1997, Biodistribution of an antibody-enzyme conjugate for antibody-directed enzyme prodrug therapy in nude mice bearing a human colon adenocarcinoma xenograft, Cancer Chemother. Pharmacol. 40:277–284.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1999 Springer Science+Business Media New York
About this chapter
Cite this chapter
Bagshawe, K.D., Napier, M. (1999). Early Clinical Studies with ADEPT. In: Melton, R.G., Knox, R.J. (eds) Enzyme-Prodrug Strategies for Cancer Therapy. Springer, Boston, MA. https://doi.org/10.1007/978-1-4615-4823-2_8
Download citation
DOI: https://doi.org/10.1007/978-1-4615-4823-2_8
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4613-7186-1
Online ISBN: 978-1-4615-4823-2
eBook Packages: Springer Book Archive